2seventy bio (TSVT) Company Revenue

2seventy bio, Inc. (TSVT) develops advanced immune cell modification methods to combat oncology. The company's sales structure and volume confirm this potential, where 0.05 determines this parameter level. Strong pricing power in the CAR-T therapy segment and inelastic demand for Abecma support revenues, while strict adherence to FDA regulations regarding biomaterial disposal ensures operational stability.

TSVT - 2seventy bio, Inc Company Sales over the range 07/04/2022 - 05/24/2025

Comprehensive metric breakdowns and analytics for 2seventy bio (TSVT)

- market price and analyst price targets:

Market Price 2seventy bio, Inc|TSVT - Price Target Chart

- market capitalization details:

Market Value 2seventy bio, Inc.|TSVT - Total Company Value

- book capitalization information:

Net Assets per Single Share 2seventy bio|TSVT - Company Net Assets|Market Value to Book Value 2seventybio.com|TSVT - Company Total Assets

- company liabilities and liquidity data:

- earnings and market ratios statistics:

TSVT - Net Income|Future Net Profit 2seventy bio, Inc.|TSVT - P/E Multiple|Future Price to Earnings Multiple 2seventybio.com|TSVT - PEG Multiple|Company Value to EBITDA 2seventy bio, Inc.|TSVT - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year 2seventy bio|TSVT - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth 2seventybio.com|TSVT - Earnings per share growth in current year|Net earnings per share change forecast for next year 2seventy bio, Inc.

- issuer revenue and sales details:

TSVT - Company Sales|Company Expected Sales Volume 2seventy bio, Inc|TSVT - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio 2seventy bio, Inc.

Comprehensive company analysis:2seventy bio, Inc TSVT

Mass-produced product of 2seventy bio, Inc.

Daily revenue monitoring allows for the verification of the actual effectiveness of the commercial strategy, eliminating accounting distortions and providing prompt signals regarding the risk of capital degradation. By analyzing the aggregate sales volume of the company, an investor assesses the ability of 2seventy bio (TSVT) to monetize the technological superiority of Abecma within the CAR-T therapy segment, where rigid demand inelasticity provides the issuer with exceptional pricing power.

Key competitors